background: Several data have demonstrated the efficacy of metformin in inducing ovulation in patients with polycystic ovary syndrome (PCOS), however, the exact mechanism by which this drug acts remains unknown. The aim of the present study was to evaluate whether the efficacy of the drug in patients with PCOS is related to a systemic hormonal -metabolic improvement, or to a local action on the ovary. methods: Twenty-four normal weight patients with PCOS, who were treated with metformin, were enrolled. Of these, 12 subjects were anovulatory (Group A1), whereas the other 12 were ovulatory but had failed to conceive (Group A2). A further 24 untreated subjects who were scheduled for laparoscopic surgery were enrolled as controls, 12 anovulatory patients with PCOS scheduled for laparoscopic myomectomy (Group B1) and a further 12 non-PCOS participants were scheduled for diagnostic laparoscopy (Group B2). Clinical assessments and biochemical evaluations in blood and antral follicular fluid were performed in each participant.
Introduction
Metformin is the treatment of choice for patients with non-insulin-dependent diabetes mellitus, after dietary manipulation showing consistent results in terms of glycaemic control (Johnson et al., 2002) . More recently, metformin, as well as other insulin-sensitizing drugs, has been introduced for the treatment of women with polycystic ovary syndrome (PCOS), on the basis of the finding that insulin resistance, with the associated compensatory hyperinsulinaemia, is likely to be a key factor in the pathogenesis of the syndrome (Dunaif, 1997) .
The results of several studies have demonstrated that metformin can induce regular menstrual cycles and increase ovulation in patients with PCOS, although the efficacy of the drug is extremely variable both between different PCOS populations and within the same population (Palomba et al., 2009a) .
The exact mechanism of the action of metformin in patients with PCOS is still unknown. However, metformin exerts a systemic action on the regulation of glucose metabolism by insulin (Palomba et al., 2009a) , and indices of insulin resistance are strong predictors of the efficacy of metformin therapy (Palomba et al., 2009b) , which suggests that the drug could act to induce ovulation as a result of the improved metabolic control. However, there is no evidence of alternative and/or adjunctive effects to its action in insulin sensitization, and a cause-effect relationship between the amelioration of PCOS and restored ovulation has not yet been demonstrated (Palomba et al., 2009a) . In addition, peripheral effects of metformin have been found to be dependent on or independent of insulin sensitization in several experimental studies, but thus far the available data have been unable to clarify the exact mechanisms by which metformin restores ovarian function (Palomba et al., 2009a) .
The aim of the present study was to evaluate whether the effects of metformin on ovulation is related to a systemic hormonal -metabolic improvement or to local action on the ovary in patients with PCOS.
Materials and Methods
The procedures used were in accordance with the guidelines of the Helsinki Declaration on Human Experimentation and the Good Clinical Practice guidelines. The study was approved by the Institutional Review Board of the Department of Obstetrics and Gynaecology, University 'Magna Graecia' of Catanzaro, Italy. The purpose of the protocol was explained carefully to all the patients and written consent was obtained before the study began.
Patients
Our cases were selected from a large population of patients who were referred to our Academic Centre of Reproductive Medicine and Surgery between October 2001 and October 2008 with anovulatory infertility (Fig. 1) . They comprised 24 young, unrelated, normal weight patients with PCOS who had had received metformin treatment to induce ovulation and were scheduled for laparoscopy (Group A; Fig. 1 ).
The diagnosis of PCOS was based initially on the presence of both chronic anovulation and clinical and/or biochemical hyperandrogenism (Zawadzki and Dunaif, 1992) . All patients with PCOS originally had bilateral polycystic ovaries (PCO), as defined by diagnostic criteria published previously (Adams et al., 1986) . All patients with PCOS had received the same metformin regimen (two 850 mg tablets daily) for 1 year.
Twelve participants were anovulatory (Group A1) despite treatment, whereas the other 12 patients had cycled normally during the previous consecutive six cycles but had failed to conceive (Group A2).
Laparoscopy was scheduled in the anovulatory patients (Group A1) to perform an ovarian drilling procedure and in the ovulatory patients (Group A2) to complete the diagnostic work-up of infertility, according to our institutional guidelines.
A further 24 patients were enrolled as controls (Group B; Fig. 1 ). Specifically, 12 untreated patients with PCOS (diagnosed according to the aforementioned criteria and with the ultrasound appearances of PCO) (Adams et al., 1986; Zawadzki and Dunaif, 1992) were selected from a population with uterine fibroids and scheduled for laparoscopic myomectomy (Group B1, controls for Group A1). In addition, 12 women with normal menstrual cycles were selected from a population of subjects scheduled for diagnostic laparoscopy because they were referred with chronic pelvic pain (Group B2, controls for Group A2).
Clinical and/or biochemical hyperandrogenism and PCO on ultrasound were excluded in all patients in Group B2. In patients of Group A2, ovulation was confirmed by serial assays of plasma progesterone (P) (.10 ng/ ml) performed monthly 7 days before the expected menses. In Groups A1 and B1 ovulation was excluded by serial plasma P (,3 ng/ml) randomly performed.
For cases and controls, the following were considered to be exclusion criteria: age less than 18 or greater than 35 years; body mass index (BMI, kg/m 2 ) less than 18 or greater than 25; major medical disorders and/or current or previous use of hormonal and/or metabolic drugs; tubal or male factor infertility or subfertility (as excluded by hysterosalpingogram and semen analysis, respectively; Male Infertility Best Practice Policy Committee of the American Urological Association, 2006; Practice Committee of the American Society for Reproductive Medicine, 2006); organic pelvic diseases at laparoscopy (or further pathology other than uterine fibroids for Group B1) or diseases that could potentially affect Figure 1 Study design. the ovarian environment; and the intention to start a diet or a specific programme of physical activity.
Protocol
Pretreatment clinical, biochemical and ultrasonographic parameters before the administration of metformin to Groups A1 and A2 were acquired retrospectively, whereas all other data were evaluated prospectively at the time of admission to hospital. All participants underwent clinical evaluation, blood sampling, transvaginal ultrasonography and laparoscopy during their admission. All of these procedures were performed during the early proliferative phase of the menstrual cycle (2nd 2 3rd days) in patients from Groups A2 and B2, and at random times in patients from Groups A1 and B1.
The clinical evaluation consisted of recording the history, gynaecological examination, anthropometric measurements [which included height, weight, BMI and waist-to-hip ratio (WHR)] and evaluation of the Ferriman -Gallwey score (Ferriman and Gallwey, 1961) . Blood samples were taken between 8:00 a.m. and 9:00 a.m. after an overnight fast for 12 h during which the participant had been resting in bed, and a complete hormonal and metabolic evaluation was performed on each subject. Finally, each patient underwent a transvaginal ultrasonographic examination by the same experienced operator (TR), who was blinded to the hormonal and clinical data, using the same ultrasonic scanner (Aplio, Toshiba Medical Systems, Rome, Italy) equipped with a 7.5 MHz vaginal probe. The ovarian dimensions and morphology and the number of antral follicles (follicular diameter ranged from 2 to 9 mm) were evaluated bilaterally and recorded in each subject. In particular, the ovaries were visualized and their dimensions were obtained by measuring the three main diameters and applying the ellipsoid formula (D 1 Â D 2 Â D 3 Â p/6). Ovarian morphology was defined as either PCO or not PCO (Adams et al., 1986) .
On the following day, all subjects underwent laparoscopic surgery performed by the same experienced operator (FZ). After production of a pneumoperitoneum using a Verres needle, a 10-mm video laparoscope was inserted infraumbilically, followed by the lateral insertion of a 5-mm ancillary trocar into each iliac fossa. A careful inspection of the pelvic cavity was performed in each patient to exclude other pelvic diseases.
Firstly, the antral follicles on the ovarian surface were visualized and each one was aspirated with a 1 ml syringe and a 26 gauge needle. Follicular fluid was collected from both ovaries in each patient. After confirmation that the initial aspiration of follicular fluid was not contaminated by blood, the follicular aspirates were independently transferred to the laboratory on dry ice, centrifuged at 250 revolutions per min for 5 min and the granulosa cells were removed. Thereafter, the remaining follicular fluid was centrifuged, and the supernatant was stored at -208C until it underwent biochemical analysis.
Thereafter, Groups A1 and B1 were treated with ovarian diathermy and myomectomy, respectively, according to standard procedures described previously (Palomba et al., 2004 (Palomba et al., , 2007a . No follicular fluid was collected from ovaries with dominant and/or persistent follicles and/or corpora lutea.
Biochemical assays
The hormonal evaluation consisted of assays of serum FSH, LH, thyroidstimulating hormone (TSH), prolactin (PRL), estradiol (E 2 ), P, 17-OH-progesterone (17-OHP), total testosterone (T), androstenedione (A), dehydroepiandrosterone sulfate (DHEAS) and sex-hormone binding globulin (SHBG).
The metabolic assessment included the evaluation of fasting glucose and insulin levels. Insulin resistance was evaluated using the homeostasis model analysis (HOMA) [fasting glucose (mmol/l) Â fasting insulin (mU/ml)/ 22.5] (Matthews et al., 1985) and the fasting glucose-to-insulin ratio (GIR) (mg/10 24 U) (Legro et al., 1998; Ducluzeau et al., 2003) . Finally, the free androgen index (FAI) [T (nmol/l)/SHBG Â 100] (Morley et al., 2002) was calculated for each participant. Concentrations of insulin growth factor (IGF)-I and IGF-II, IGF binding protein (BP)-1 and IGFBP-3, T, A, E 2 and the A/E 2 ratio were evaluated in each sample of antral follicular fluid. All hormone concentrations in blood and antral follicular fluid were measured by specific radioimmunoassay (RIA). LH, FSH, E 2 , PRL, TSH, DHEAS, T and A were measured by double-antibody RIA: Radim kits (Rome, Italy) were used for LH and FSH; Sorin kits (Saluggia, Italy) for PRL, TSH, DHEAS, A and T; and a Biodata kit (Rome, Italy) for E 2. Levels of 17-OHP were determined with an RIA from Diagnostic Systems Laboratories 5000 (Webster, TX, USA); whereas the levels of SHBG were measured with an immunoradiometric assay (IRMA) from Radim. Plasma glucose levels were determined by the glucose oxidase method on a Beckman Glucose Analyzer (Beckman Coulter, Inc., Fullerton, CA, USA), and serum insulin was measured by a solid-phase chemiluminescent enzyme immunoassay using a commercially available kit (Immunolite Diagnostic Products Co, Los Angeles, CA, USA). The levels of IGF-I and IGF-II in antral follicular fluid were measured by IRMA (Radim) after acid-ethanol extraction, whereas concentrations of IGFBP-1 and IGFBP-3 were assayed by two-site RIA (Diagnostic Systems Laboratories). The intra-assay and inter-assay coefficients of variation (CV) for each biochemical or hormonal parameter were evaluated, and the values of the CVs ranged from 1.2 to 5.2%.
Statistical analysis
The normal distribution of continuous variables was evaluated with the use of the Kolmogrov-Smirnov test, and continuous data were expressed as the mean + standard deviation (SD). Continuous variables were analysed with one-way analysis of variance (ANOVA) and ANOVA for repeated measures, and the Bonferroni test was used for post hoc analysis.
For categorical variables, the Pearson x 2 test was performed; Fisher's exact test was used for the frequency tables when more than 20% of the expected values were lower than five. A simple linear regression analysis was used to establish the relationships between the variation (D) in plasma T levels (DT) and HOMA (DHOMA), which were considered to be indicators of the effect of treatment on hyperandrogenism and on insulin resistance and all the follicular fluid factors. A bivariate two-tailed correlation analysis was performed by calculating the Spearman's coefficient (Spearman's rho, r), and the significance of the correlation was set at the 0.05 level. The level of statistical significance was set at P , 0.05 for all statistical analyses. The Statistics Package for Social Sciences (SPSS 14.0.1, 18 November 2005; SPSS Inc., Chicago, IL, USA) was used for all calculations.
Results
In our population, PCOS was diagnosed initially according to the criteria of the National Institutes of Health (NIH); the criteria of the European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group, 2004 ) and the Androgen Excess and PCOS Society (AEPS; Azziz et al., 2006) were also satisfied. The clinical, hormonal and metabolic data from all groups are shown in Table I .
The clinical, instrumental and biochemical assessments confirmed the anovulatory state in all patients in Groups A1 and B1 who underwent surgery. After treatment with metformin, levels of T, A, SHBG and fasting insulin, as well as FAI, GIR and HOMA, were improved significantly (P , 0.05) in both Group A1 and Group A2. , estradiol; FAI, free androgen index; GIR, glucose-to-insulin ratio; HOMA, homeostasis model analysis; IGF, insulin growth factor; IGFBP, IGF binding protein; P, progesterone; PRL, prolactin; SHBG, sex-hormone binding globulin; T, total testosterone; TSH, thyroid-stimulating hormone; WHR, waist-to-hip ratio.
A significant difference (P , 0.05) between Groups A1 and A2 was observed with regards to the levels of SHBG, fasting insulin, GIR and HOMA before treatment; these differences were sustained after treatment (Table I) .
In Groups A1 and A2, serum levels of LH, T, A, DHEAS, SHBG and fasting insulin, as well as the Ferriman -Gallwey score, FAI, GIR and HOMA, were significantly better than those in Group B1 (P , 0.05) and significantly worse than those in Group B2 (P , 0.05). No difference in the mean variation of any clinical, hormonal or metabolic parameter was observed between Groups A1 and A2 (Table I) .
Before treatment, all patients with PCOS had bilateral PCO. After treatment with metformin, the ovarian morphology had changed in one patient from Group A1 and nine subjects from Group A2 [1/ 12 (8.3%) versus 9/12 (75.0%), respectively; P , 0.001]. In particular, two patients from Group A2 showed no PCO morphology, whereas unilateral PCO morphology was observed in the others.
The ovarian dimensions (cm 3 ) that were measured in cases and controls are shown in Fig. 2 . Before treatment with metformin, no significant difference was observed in the ovarian dimensions between Groups A1 and A2 (14.02 + 1.11 versus 13.92 + 1.28 cm 3 , respectively). At the same time, the ovarian dimensions were not significantly different between Groups A1 and A2 and Group B1 (13.72 + 1.21), but they were significantly greater (P , 0.05) in Groups A1 and A2 than in Group B2 (6.49 + 1.36 cm 3 ). After administration of metformin, the ovarian dimensions were unchanged in Group A1 (14.02 + 1.11 versus 13.53 + 1.47 cm 3 , baseline versus post-treatment values, respectively; P ¼ 0.431) and were not significantly different compared with those of Group B1 (13.53 + 1.47 versus 13.69 + 1.28 cm 3 baseline versus post-treatment values, respectively; P ¼ 0.764). On the other hand, the ovarian dimensions in Group A2 assessed after treatment were significantly lower than those observed in the pretreatment evaluation (13.88 + 1.28 versus 11.67 + 1.71 cm 3 ; P ¼ 0.009), although they were significantly higher than those of Group B2 (11.67 + 1.71 versus 6.49 + 1.36 cm 3 ; P , 0.001; Fig. 2 ). The laparoscopy procedures were completed successfully in all cases without any complications. In Groups A1, A2, B1 and B2, follicular fluid was aspirated from a total of 81, 74, 89 and 38 antral follicles, respectively. No dominant or persistent follicles and/or corpora lutea were present at laparoscopy in any of the participants. Table II shows the concentrations of IGF-I and IGF-II, IGFBP-1 and IGFBP-3, T, A, E 2 and the A/E 2 ratio from the follicular fluid. Significant differences (P , 0.05) in the concentrations of IGF-II, IGFBP-1 and IGFBP-3, T, A, E 2 and the A/E 2 ratio in antral follicular fluid were observed between Groups A1 and A2. In addition, the concentrations of all these parameters in the follicles were significantly different (P , 0.05) for both Group A1 versus Group B1 and Group A2 versus Group B2.
Analysis of the antral follicular fluid from treated ovaries with PCO or non-PCO morphology showed significant differences (P , 0.05) in the concentrations of IGF-II, IGFBP-1 and IGFBP-3, T, A, E 2 and the A/E 2 ratio between the two ovarian morphologies (Table III) .
The correlations between DT and DHOMA, and follicular fluid factors, in Groups A1 and A2 are shown in Table IV . In Group A1, no significant correlation was observed between DT and DHOMA or any factor in the follicular fluid. Conversely, in Group A2, significant correlations were detected between DT and IGF-II (r ¼ 20.611; P ¼ 0.035) and IGFBP-1 (r ¼ 20.607; P ¼ 0.036), and between DHOMA and IGF-II (r ¼ 0.634; P ¼ 0.042), A (r ¼ 20.582; P ¼ 0.029) and the A/E 2 ratio (r ¼ 20.656; P ¼ 0.019).
Discussion
To our knowledge, this experimental study is the first report of an evaluation of the effect of 1 year of metformin administration on the ovary in unstimulated menstrual cycles in a well selected sample of patients with PCOS. We analysed the effects of metformin in responders and non-responders among patients with PCOS (cases) by studying the clinical and biochemical changes in blood and antral follicular fluid, in comparison with untreated anovulatory patients with PCOS and healthy women (controls). Although patients with PCOS are frequently overweight or obese, in the present study we decided to include participants of normal weight only, in order to exclude any potential confounding factor related to body weight that may affect ovarian function (Pasquali et al., 2003) and to study a population that is more sensitive to the action of metformin (Baillargeon et al., 2004; Onalan et al., 2005; Legro et al., 2008; Palomba et al., 2009b) .
The systemic effects of metformin have been demonstrated extensively. In fact, several experimental and clinical studies, most of them translated from a population of patients with type 2 diabetes mellitus, have shown that this drug acts by systemic effects on hepatic gluconeogenesis and the production of SHBG, intestinal free fatty acid oxidation and glucose use and the utilization of glucose by peripheral tissues (Palomba et al., 2009a) .
The current study confirmed that patients who ovulated although they received treatment with metformin were more insulin resistant initially than patients who remained anovulatory under treatment (Palomba et al., 2009b) and that 12 months of treatment with who did not ovulate (Group A1) and those who ovulated (Group A2) before and during treatment with metformin, and in PCOS-affected (Group B1) and healthy (Group B2) controls. *P , 0.05 versus Groups A1/A2 and Group B1; 8P , 0.05 versus pretreatment. metformin affected insulin sensitivity in patients with PCOS, irrespective of their ovulatory or anovulatory state (Palomba et al., 2007b) .
In particular, patients with PCOS who ovulated, as well as those who remained anovulatory under treatment, showed an improved metabolic and hormonal pattern when compared with untreated anovulatory controls with PCOS. Similarly, metformin reduced biochemical hyperandrogenism in both anovulatory and ovulatory patients with PCOS to a similar degree, as determined from the analysis of the variation in serum androgens in both treated PCOS groups. However, an unexpectedly greater decrease in the level of serum androgens was observed in patients with PCOS who remained anovulatory under metformin treatment, whereas a greater reduction in the indices of insulin resistance was observed in patients with PCOS who ovulated under treatment. Moreover, the size of the variation in the parameters that changed was not different between ovulatory and anovulatory patients with PCOS under metformin treatment. In addition, administration of metformin did not normalize either the indices of insulin resistance or the level of androgens, as confirmed by comparison with the healthy controls.
All of these findings seem to suggest that the systemic effects of metformin are not related so strongly to the clinical (ovarian) response and that the determinants of the ovulatory response to metformin should not be considered to be related solely to the systemic effect of the drug on insulin sensitivity and/or on hyperandrogenism. Thus, additional or alternative mechanisms should be proposed. Several authors have suggested that some of the efficacy of metformin in PCOS may be related to local actions on ovarian steroidogenesis Jakubowicz, 1996, 1997; Attia et al., 2001) , and on autocrine and paracrine insulin-related signalling (Erickson et al., 1990; Sonnatag et al., 2005; Tosca et al., 2006 Tosca et al., , 2007 Coyral-Castel et al., 2008) . In this regard, metformin was demonstrated to inhibit the production of androgens by thecal cells by inhibiting the expression of steroidogenic acute regulatory protein and 17a-hydroxylase (Attia et al., 2001) , and to decrease the activity of ovarian cytochrome P450c17a Jakubowicz, 1996, 1997) in thecal cells. On the other hand, metformin reduces the bioavailability of IGFs, which results in the impairment of the control of granulosa cells by gonadotrophins (Erickson et al., 1990; Sonnatag et al., 2005) . In addition, in bovine granulosa cells, metformin decreases steroidogenesis and the phosphorylation of the mitogenactivated protein kinases (MAPKs) by activating the 5 0 -AMP-activated protein kinase (AMPK) (Tosca et al., 2006 (Tosca et al., , 2007 Coyral-Castel et al., 2008) . The latter is a pleiotropic serine/threonine kinase that plays a role in the control of granulosa cell steroidogenesis and nuclear maturation in oocytes in several species (Coyral-Castel et al., 2008) .
Our study confirmed a local effect of metformin, which seemed to have two mechanisms of action on the ovary: (i) it improved ovarian insulin resistance, and (ii) it reduced the levels of intrafollicular androgens. In particular, we detected a significant effect of metformin on IGFs and IGFBPs, as shown previously by Stadtmauer et al. (2001) , although in that study, several confounding factors, such as hyperstimulation of ovarian gonadotrophins, were present. On the other hand, we found a significant effect of metformin on hyperandrogenism in the follicular fluid. In fact, significant differences in the concentrations of T, A, E 2 and the A/E 2 ratio in the follicular fluid were observed between treated and untreated patients with PCOS.
Notwithstanding the many studies that have been published on metformin treatment in patients affected by PCOS, no data are available to date on the novel local (ovarian) effect of metformin in relation to the clinical response. In this regard, the present study is probably the first attempt to define the contribution of the systemic and/or local effects of the administration of metformin in patients with PCOS.
The analysis of follicular fluid seemed to confirm (Palomba et al., 2009a ) that metformin acts directly on the ovary improving local levels of androgens, ovarian insulin resistance and the levels of several growth factors. Our hypothesis regarding metformin effects on follicular development is depicted in Fig. 3 . Significant differences in follicular fluid factors were reported between treated and untreated patients with PCOS, who received laparoscopic myomectomy, and in which it was hypothesized that uterine fibroids were not affecting ovarian hormonal environment since no correlation between the syndrome and leiomyomas has been at the moment demonstrated. Moreover, the analysis of antral follicular fluid showed that metformin had a differential and peculiar action on the ovary that is related strongly to the clinical response. It was not possible to compare the results of the analyses of follicular fluid with pretreatment concentrations of the factors in follicular fluid. However, ovarian androgen levels and markers of insulin resistance showed a greater improvement in women with PCOS who were able to ovulate during treatment with metformin than in those who remained anovulatory, despite the fact that both ovulatory and anovulatory participants showed a similar improvement in systemic hormonal and metabolic parameters.
A simple linear regression analysis was performed to establish the relationship between factors in the follicular fluid and the systemic response to the treatment, which included DT and DHOMA as indicators for improved hyperandrogenism and insulin resistance, Figure 3 Hypothesis for metformin effects on follicular development. respectively, and revealed very interested findings. In this regard, our data suggested that ovaries in our population with PCOS showed a differential sensitivity to metformin, and that an improved biochemical response to metformin by a 'sensitive' ovary could be decisive for the clinical response. In fact, in ovulatory patients with PCOS, significant correlations were detected between the variation in plasma T levels and IGF-II and IGFBP-1 in follicular fluid, and between the variation in HOMA and IGF-II, A and the A/E 2 ratio in follicular fluid (Fig. 3) . On the other hand, patients with PCOS who were anovulatory under metformin seemed to have a local 'resistance' to the treatment. In fact, no significant correlation between the variation in plasma T levels and HOMA, or with any follicular fluid factor, was observed in these patients.
Finally, the current study analysed the effects of metformin on ovarian morphology. Although the importance of ovarian structure is controversial (Adams et al., 2004; Legro et al., 2005; Murphy et al., 2006) and changes in ultrasonographic morphology with time are a common finding in women with PCOS, our results showed significant changes in both the dimensions and morphology of the ovaries only in women with PCOS who ovulated under treatment. Thus, ovarian morphology seemed to be an epiphenomenon of the improved local hormonal status associated with metformin treatment, even when only one ovary was considered. In fact, in approximately 58.3% of patients, evidence of changes in PCO morphology only appeared unilaterally. In this regard, significant differences in intra-ovarian follicular fluid indices of hyperandrogenism and insulin resistance were observed between PCO and non-PCO ovaries from women under metformin treatment.
In conclusion, the current study demonstrates that the efficacy of metformin in inducing ovulation in patients with PCOS is probably due to a direct action of the drug on the ovary, and that the ovulatory response to the drug seems to be related more to local drug sensitivity or resistance than to improvements in the systemic hormonal and/or metabolic pattern.
